PLAN FOR PROTECTION OF THE ARMY FORCE AGAINST ENDEMIC

File: 120396_sep96_decls82_0002.txt
Page: 0002
Total Pages: 13

Subject: PLAN FOR PROTECTION OF THE ARMY FORCE AGAINST ENDEMIC           

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003203

Folder Title: PLAN FOR PROTECTION OF THE ARMY FORCE AGAINST ENDEMIC DISEASES                                  

Document Number:          1

Folder SEQ  #:         96











         national emergencies The Surgeon General (TSG) will make a
         determination whether the safety record of the vaccine can be used
         without informed consent. FDA will be consulted.

             C. The IND products have demonstrated their effectiveness
         through animal studies and/or limited human trials, with no
         substantial adverse outcomes. Some of these IND products have
         limited civilian applicability, but have been developed against
         worldwide threats of military importance. Development of most of
         these products is under the direction of the commander, U.S. Army
         Medical Research and Development Command.
             d. Of concern is the time factor limitation for delivery and
         administration of vaccine(s) to ensure timely immunization of Army
         personnel. The plan must take into consideration the time required
         to ship and vaccinate, and the need to administer additional doses
         several days to weeks apart with many of the vaccines. Immunity
         cannot be assumed until approximately two weeks after
         administration of the vaccine or toxoid. Immunity with immune
         globulin preparations occurs soon after immunization.

             e. There is a limited industrial base for the production of
         these vaccines. This plan will address this limitation by
         stockpiling these products, providing the Army with a viable
         capability to address these threats. This plan is designed to
         provide time for the industrial base to produce additional stocks
         of vaccines.

         4. Committees.

             a. The Surgeon Generalls Vaccination Policy and Review
         Committee (SGVPRC) is chaired by the Deputy Surgeon General.
         Permanent members will be Director, Health Care Operations;
         Director, Professional services, and Commander, U.S. Army Medical
         Research and Development Command. The committee is responsible for
lowing:

                 (1) Recommend to TSG policies for the procurement,
         utilization, and distribution of contingency vaccines, toxoids, and
         immune globulins.

                 (2) During times of mobilization or other national
         emergencies determine expedient use of contingency vaccines.

                 (3) Conduct annual reviews of the procurement,
         utilization, and distribution plan for contingency vaccines within
         the Army.
                                                                                   is

                                            2

Document 13 f:/Week-36/BX003203/PLAN FOR PROTECTION OF THE ARMY FORCE AGAINST ENDEMIC DISEASES/plan for protection of the army force against en:11259610132722
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = PLAN FOR PROTECTION OF THE ARMY FORCE AGAINST ENDEMIC DISEASES
Folder Seq # = 96
Subject = PLAN FOR PROTECTION OF THE ARMY FORCE AGAINST EN
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 25-NOV-1996